Obsessive Compulsive DisorderNCT01590862
ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators
A study testing Deep Brain Stimulator in people with Obsessive Compulsive Disorder and Major Depressive Disorder, run by Massachusetts General Hospital at 2 sites in United States.
Trial summary
We propose to study approach/avoidance behavior as measured by the Approach Avoidance task in 20 epilepsy patients undergoing implementation of depth electrodes for seizure monitoring in the Epilepsy Monitoring Unit at MGH. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Obsessive Compulsive Disorder, Major Depressive Disorder, Epilepsy
- What is being tested?
- Deep Brain Stimulator
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 2 sitesUnited States
- Study dates
- 23 Jan 2021to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Deep brain stimulator implantation performed at least three months prior to study
- Right-handed (as determined by the Handedness Inventory; Oldfield,1971)
- Normal or corrected-to normal vision and hearing
- Current diagnosis of MDD or OCD
Who cannot join
- Subjects unable to visualize stimulus objects with correction
- Dementia or other known cognitive deficit
- Psychiatric Patients:
- Clinical history of bipolar disorder
- Current or past psychotic disorder
- Gross structural brain damage
Show all 11Show fewer
- Cognitive impairment that would affect a participant's ability to give informed consent
- Current substance abuse, or abuse within the past 3 months
- Clinical history of severe personality disorder
- Imminent risk of suicide or an inability to control suicide attempts
- Evidence of dementia or other significant cognitive impairment on neuropsychological evaluation
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Massachusetts General Hospital
Boston, Massachusetts, 02114
Massachusetts General Hospital
Charlestown, Massachusetts, 02129
About this study
We propose to study approach/avoidance behavior as measured by the Approach Avoidance task in 20 epilepsy patients undergoing implementation of depth electrodes for seizure monitoring in the Epilepsy Monitoring Unit at MGH. We will also study the effects of VC/VS electrical stimulation on approach-avoidance conflict in 20 adult patients who have undergone DBS implantation for severe MDD and/or OCD. There are 100-200 patients in the world with DBS electrodes in the VC/VS, and our research team cares for more than any other institution. Both participant groups will be assessed with respect to reward-aversion decision conflict using the task. The task will be performed with concurrent EEG recordings in DBS patients, and with continuous recording through our invasive neurophysiology rig in EMU subjects.
Read the detailed description
DBS Patients:
The study will take place at a clinical office in the Charlestown Navy Yard (CNY), and will consist of one 8 hour visit with an optional second 8 hour visit, for a potential total of 16 hours. Study staff will schedule a convenient time for patients to arrive, or the research visit may be paired with a regularly scheduled DBS programming visit. A member of the Division of Neurotherapeutics authorized to manipulate DBS programming will turn the device on and off during the study. The subject's therapeutic parameters of the DBS system will not be changed. The subject will be asked to complete several questionnaires Beck Depression Inventory-II, Quick Inventory of Depressive Symptomatology, Snaith Hamilton Pleasure Scale, Mood and Anxiety Symptoms Questionnaire, and the Cognitive-Behavioral Avoidance Scale.
Following these questionnaires, a member of the study staff will teach the subjects to perform a modified version of the Approach-Avoidance task (adapted from Aupperle et al., in press and Amemori \& Graybiel, 2012). Participants will be given a choice between a monetary reward (approach condition) plus an aversive stimulus (mild electric current further described below) or no monetary reward plus no aversive stimulus (avoid condition). Two partially filled rectangles (one red and one blue) will indicate the relative amount of potential punishment and reward. Subjects will use a joystick to direct a circle from a center fixation point to select either a plus sign associated with the approach condition or a square associated with the avoid condition. Subjects therefore control the outcome of each trial and whether or not they receive any aversive stimuli. After the task, participants will complete the AAC Task: Post-Questionnaire (adapted from Aupperle et al.)
The aversive stimulus is delivered in the form of a mild half second stimulation to the ankle at a level of their choice that is uncomfortable but not painful. This electrical current is produced by the Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013). Patients will complete the task with DBS ON and DBS OFF. Because we are not changing the therapeutic parameters of stimulation, subjects should not experience any changes during the ON condition. Should any discomfort arise in the OFF condition, the subject will be able to terminate the study and return to the ON condition immediately.
Electroencephalography recordings (EEG) will be collected at 1450 Hz throughout the task in the ON and OFF conditions, using a Brain Research Products 96-channel active EEG system. Before each task run, we will also collect eyes-open and eyes-closed resting data, aiming for at least 1 min of data free from any eyeblink, muscle, or other artifact. All recordings will take place in a sound-isolated room, with careful scalp and electrode preparation to keep impedances under 5 kΏ. Ground/references will be in the midline to minimize hemispheric effects, and simultaneous EOG will permit blink/eyeroll artifact correction. The EEG system includes a camera, tracking devices, and software optimized for registration. All electrode positions will be digitized and referenced to subjects' pre-operative MRIs, enabling source-localized analysis.
Epilepsy Patients:
We will administer the same Ap-Av task in 20 epilepsy patients undergoing implantation of depth electrodes for seizure monitoring in the Epilepsy Monitoring Unit at MGH. Epilepsy unit experiments will involve both recording and stimulation. Recordings with the Ap-Av task will be collected throughout the clinical stay. At the end of the stay, there are 1-2 days when the patient resumes anti-seizure medications and the risk of a stimulation induced seizure is low. On those days, we will attempt to modify task behavior through stimulation. Based on our prior experience, we expect to test 1-2 stimulation targets per patient. In the first 10 patients, we will seek to replicate results that pregenual ACC stimulation leads to increased avoidance. On a randomly selected 50% of trials (interleaved so that patients are blind to stimulation), we will bilaterally stimulate the pregenual ACC (single bipolar pair per hemisphere) at 130 Hz and 2 mA, for 600 ms during cue presentation. In the subsequent 10 patients, we will attempt to extend the result that dACC theta power predicts approach behavior. When theta power rises above a set threshold (determined during the recording-only days), we will again stimulate the pACC.
For patients who have been implanted with clinical intracranial electrodes (whether or not they have also been implanted with research electrodes), additional scalp electrodes may be used. Usually, some electrodes are placed on the scalp for clinical purposes (as decided on by the clinical team). Patients receiving depth electrodes, for example, usually receive a standard set of scalp electrodes as well. However, if the clinical team decides that only a very small number of electrodes are needed for their purposes we may supplement this further with less than 10 additional electrodes. For this purpose, routinely-used clinical scalp electrodes (including EOG and EMG) will be employed. The exact number and placement will be constrained by clinical parameters. Specifically, regions close to any wound will be avoided to minimize the risk of infection. Also, as the clinical recording systems have limited numbers of channels, additional recording electrodes will be limited to what channels are available. In cases where a full set of scalp electrodes are used, the amount of time they are on the patient's head will be limited to approximately one day to decrease the risk of infection. This additional recording will be done one day before the scheduled date for removal of the intracranial electrodes.
- Being tested
- Deep Brain Stimulator
- Medical subject headings
- Obsessive-Compulsive Disorder, Depressive Disorder, Major, Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deep Brain StimulatorDevice
Medtronic Deep Brain Stimulation device turned on and off
| Study group | Role | What they receive |
|---|---|---|
| Deep Brain Stimulation On | Active comparator | We will assess Reward Motivation behavior with Deep Brain Stimulation on. Receives: Device: Deep Brain Stimulator |
| Deep Brain Stimulation Off | No intervention | We will assess Reward Motivation behavior with Deep Brain Stimulation off. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Approach Avoidance Task
The Approach Avoidance task is a computer task that assesses approach avoidance behavior. We will assess whether stimulation of the Ventral Capsule/Ventral Striatum has an effect on behavior by executing this task with the DBS system on and off.
Measured: Up to 8 hours for each visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2012 (estimated)
- Study start23 Jan 2021
- Primary completion31 Mar 2026
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obsessive Compulsive DisorderStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Todd Herrington, MD, PhD, Massachusetts General Hospital
- Investigators
- Darin Dougherty, MD, Principal investigator, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01590862
- Sponsor's protocol ID
- 2011P002821
- Status last verified
- Apr 2026
- First submitted
- 27 Apr 2012
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators
- ClinicalTrials.gov ID
- NCT01590862
- Acronym / sponsor ID
- 2011P002821
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Study start
- 23 Jan 2021 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 3 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We propose to study approach/avoidance behavior as measured by the Approach Avoidance task in 20 epilepsy patients undergoing implementation of depth electrodes for seizure monitoring in the Epilepsy Monitoring Unit at MGH. We will also study the effects of VC/VS electrical stimulation on approach-avoidance conflict in 20 adult patients who have undergone DBS implantation for severe MDD and/or OCD. There are 100-200 patients in the world with DBS electrodes in the VC/VS, and our research team cares for more than any other institution. Both participant groups will be assessed with respect to reward-aversion decision conflict using the task. The task will be performed with concurrent EEG recordings in DBS patients, and with continuous recording through our invasive neurophysiology rig in EMU subjects.
Detailed description
DBS Patients:
The study will take place at a clinical office in the Charlestown Navy Yard (CNY), and will consist of one 8 hour visit with an optional second 8 hour visit, for a potential total of 16 hours. Study staff will schedule a convenient time for patients to arrive, or the research visit may be paired with a regularly scheduled DBS programming visit. A member of the Division of Neurotherapeutics authorized to manipulate DBS programming will turn the device on and off during the study. The subject's therapeutic parameters of the DBS system will not be changed. The subject will be asked to complete several questionnaires Beck Depression Inventory-II, Quick Inventory of Depressive Symptomatology, Snaith Hamilton Pleasure Scale, Mood and Anxiety Symptoms Questionnaire, and the Cognitive-Behavioral Avoidance Scale.
Following these questionnaires, a member of the study staff will teach the subjects to perform a modified version of the Approach-Avoidance task (adapted from Aupperle et al., in press and Amemori \& Graybiel, 2012). Participants will be given a choice between a monetary reward (approach condition) plus an aversive stimulus (mild electric current further described below) or no monetary reward plus no aversive stimulus (avoid condition). Two partially filled rectangles (one red and one blue) will indicate the relative amount of potential punishment and reward. Subjects will use a joystick to direct a circle from a center fixation point to select either a plus sign associated with the approach condition or a square associated with the avoid condition. Subjects therefore control the outcome of each trial and whether or not they receive any aversive stimuli. After the task, participants will complete the AAC Task: Post-Questionnaire (adapted from Aupperle et al.)
The aversive stimulus is delivered in the form of a mild half second stimulation to the ankle at a level of their choice that is uncomfortable but not painful. This electrical current is produced by the Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013). Patients will complete the task with DBS ON and DBS OFF. Because we are not changing the therapeutic parameters of stimulation, subjects should not experience any changes during the ON condition. Should any discomfort arise in the OFF condition, the subject will be able to terminate the study and return to the ON condition immediately.
Electroencephalography recordings (EEG) will be collected at 1450 Hz throughout the task in the ON and OFF conditions, using a Brain Research Products 96-channel active EEG system. Before each task run, we will also collect eyes-open and eyes-closed resting data, aiming for at least 1 min of data free from any eyeblink, muscle, or other artifact. All recordings will take place in a sound-isolated room, with careful scalp and electrode preparation to keep impedances under 5 kΏ. Ground/references will be in the midline to minimize hemispheric effects, and simultaneous EOG will permit blink/eyeroll artifact correction. The EEG system includes a camera, tracking devices, and software optimized for registration. All electrode positions will be digitized and referenced to subjects' pre-operative MRIs, enabling source-localized analysis.
Epilepsy Patients:
We will administer the same Ap-Av task in 20 epilepsy patients undergoing implantation of depth electrodes for seizure monitoring in the Epilepsy Monitoring Unit at MGH. Epilepsy unit experiments will involve both recording and stimulation. Recordings with the Ap-Av task will be collected throughout the clinical stay. At the end of the stay, there are 1-2 days when the patient resumes anti-seizure medications and the risk of a stimulation induced seizure is low. On those days, we will attempt to modify task behavior through stimulation. Based on our prior experience, we expect to test 1-2 stimulation targets per patient. In the first 10 patients, we will seek to replicate results that pregenual ACC stimulation leads to increased avoidance. On a randomly selected 50% of trials (interleaved so that patients are blind to stimulation), we will bilaterally stimulate the pregenual ACC (single bipolar pair per hemisphere) at 130 Hz and 2 mA, for 600 ms during cue presentation. In the subsequent 10 patients, we will attempt to extend the result that dACC theta power predicts approach behavior. When theta power rises above a set threshold (determined during the recording-only days), we will again stimulate the pACC.
For patients who have been implanted with clinical intracranial electrodes (whether or not they have also been implanted with research electrodes), additional scalp electrodes may be used. Usually, some electrodes are placed on the scalp for clinical purposes (as decided on by the clinical team). Patients receiving depth electrodes, for example, usually receive a standard set of scalp electrodes as well. However, if the clinical team decides that only a very small number of electrodes are needed for their purposes we may supplement this further with less than 10 additional electrodes. For this purpose, routinely-used clinical scalp electrodes (including EOG and EMG) will be employed. The exact number and placement will be constrained by clinical parameters. Specifically, regions close to any wound will be avoided to minimize the risk of infection. Also, as the clinical recording systems have limited numbers of channels, additional recording electrodes will be limited to what channels are available. In cases where a full set of scalp electrodes are used, the amount of time they are on the patient's head will be limited to approximately one day to decrease the risk of infection. This additional recording will be done one day before the scheduled date for removal of the intracranial electrodes.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Deep Brain Stimulation On | Active comparator | Device: Deep Brain StimulatorWe will assess Reward Motivation behavior with Deep Brain Stimulation on. |
| Deep Brain Stimulation Off | No intervention | –We will assess Reward Motivation behavior with Deep Brain Stimulation off. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Deep brain stimulator implantation performed at least three months prior to study
- Right-handed (as determined by the Handedness Inventory; Oldfield,1971)
- Normal or corrected-to normal vision and hearing
- Current diagnosis of MDD or OCD
Key exclusion criteria (11 listed)
- Subjects unable to visualize stimulus objects with correction
- Dementia or other known cognitive deficit
- Clinical history of bipolar disorder
- Current or past psychotic disorder
- Gross structural brain damage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Deep Brain StimulatorMedtronic Deep Brain Stimulation device turned on and off | Device | Deep Brain Stimulation On |
Primary outcome
Approach Avoidance Task
Time frame: Up to 8 hours for each visit
The Approach Avoidance task is a computer task that assesses approach avoidance behavior. We will assess whether stimulation of the Ventral Capsule/Ventral Striatum has an effect on behavior by executing this task with the DBS system on and off.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
Related trials for Obsessive Compulsive Disorder
Enrolling by invitation
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
Obsessive - Compulsive Disorder, Family Accommodation
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
Recruiting
Focused Ultrasound for Behavioral Health
Depression, Anxiety
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Darin Dougherty, MD principal investigator
Massachusetts General Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Deep Brain Stimulator in people with Obsessive Compulsive Disorder and Major Depressive Disorder, run by Massachusetts General Hospital at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Approach Avoidance Task (time frame: Up to 8 hours for each visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.